NCT06252506View on ClinicalTrials.gov

Molecular Imaging Study of Harmine/DMT: a Basic Research Approach

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

February 17, 2025

Study Completion Date

March 5, 2025

Conditions
Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine
Interventions
DRUG

N,N-dimethyltryptamine (DMT) + harmine

DMT and harmine are the two most abundant chemicals in the Amazonian hallucinogenic plant brew, Ayahuasca, which is used traditionally in spiritual and healing ceremonies. An oral formulation of these two substances will be tested against placebo in the context of an FDG-PET scan.

DRUG

Placebo

Placebo will be administered on one of the study days to compare the effects of DMT and harmine with the effects a placebo administration.

Trial Locations (2)

3010

Department of Nuclear Medicine, Bern University Hospital, Bern

8032

Psychiatric University Hospital Zurich, Zurich

All Listed Sponsors
collaborator

Psychiatric University Hospital, Zurich

OTHER

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT06252506 - Molecular Imaging Study of Harmine/DMT: a Basic Research Approach | Biotech Hunter | Biotech Hunter